- Company preparing for potential commercialization of two first-in-class antibiotics, Lefamulin (IV and Oral) and CONTEPO (IV) in the United States in 2019 - - New Drug Application submissions expected in Q4 2018 - DUBLIN, Ireland , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , Aug. 08, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a clinical stage biopharmaceutical company engaged in the research and development of innovative anti-infective agents to treat serious infections, today announced that Ted
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , July 26, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced the pricing of its underwritten public offering of 18,181,818 ordinary shares at a public offering price of $2.75 per share.
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , July 25, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV) today announced that it has commenced an underwritten public offering of $50.0 million of ordinary shares. In addition, Nabriva Therapeutics expects to grant the underwriters an
DUBLIN, Ireland and KING OF PRUSSIA, Pa. and SAN DIEGO , July 25, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, today announced that
- Acquisition adds Zavante’s CONTEPO ™ , potential first-in-class in the United States injectable antibiotic for cUTIs, to Nabriva’s late-stage anti-infective portfolio - - Nabriva on track to file New Drug Applications for lefamulin and CONTEPO in the fourth quarter of 2018 - - Ted Schroeder
Potential of Lefamulin to Treat Patients with CABP Against Backdrop of Increasing Bacterial Resistance Presented on Eight Posters DUBLIN, Ireland , May 31, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and
DUBLIN, Ireland and KING OF PRUSSIA, Pa. , May 29, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents to treat serious infections, with a focus on the pleuromutilin class
- Lefamulin met all FDA and EMA primary endpoints and was shown to be generally well tolerated - - Company plans to file a New Drug Application with the U.S. Food and Drug Administration in the fourth quarter of 2018 - - Conference call and webcast today at 8:30 a.m.
- Topline data from second pivotal Phase 3 trial of lefamulin for CABP (LEAP 2) expected in Spring 2018 - - $90 million cash and investments as of March 31, 2018 expected to fund operations into the first quarter of 2020 - DUBLIN, Ireland , May 08, 2018 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc
